中国继续医学教育
中國繼續醫學教育
중국계속의학교육
CHINA CONTINUING MEDICAL EDUCATION
2015年
4期
83-83
,共1页
HAD方案%DA方案,HA方案%急性髓系白血病
HAD方案%DA方案,HA方案%急性髓繫白血病
HAD방안%DA방안,HA방안%급성수계백혈병
The HAD scheme%The DA scheme%The HA scheme%Acute myeloid leukemia
目的:探讨HAD方案诱导治疗急性髓系白血病临床疗效及不良反应。方法将58例急性髓系白血病患者随机分为2组,治疗组30人,应用HAD方案诱导治疗,对照组28人随机应用DA/HA方案诱导治疗。结果 HAD组诱导化疗完全缓解率(CR)为76.7%,部分缓解率(PR)为13.3%,总有效率为90%,DA/HA方案诱导化疗完全缓解率(CR)为32.1%,部分缓解率(PR)为28.6%,总有效率为60.7%,观察组的缓解率及总有效率明显高于对照组,P<0.05,差异有统计学意义,2组不良反应相当。HAD方案骨髓抑制及粒细胞缺乏严重程度相对DA/HA重一些。结论 HAD方案诱导化疗治疗急性髓系白血病疗效优于DA/HA方案,且毒副作用相当。
目的:探討HAD方案誘導治療急性髓繫白血病臨床療效及不良反應。方法將58例急性髓繫白血病患者隨機分為2組,治療組30人,應用HAD方案誘導治療,對照組28人隨機應用DA/HA方案誘導治療。結果 HAD組誘導化療完全緩解率(CR)為76.7%,部分緩解率(PR)為13.3%,總有效率為90%,DA/HA方案誘導化療完全緩解率(CR)為32.1%,部分緩解率(PR)為28.6%,總有效率為60.7%,觀察組的緩解率及總有效率明顯高于對照組,P<0.05,差異有統計學意義,2組不良反應相噹。HAD方案骨髓抑製及粒細胞缺乏嚴重程度相對DA/HA重一些。結論 HAD方案誘導化療治療急性髓繫白血病療效優于DA/HA方案,且毒副作用相噹。
목적:탐토HAD방안유도치료급성수계백혈병림상료효급불량반응。방법장58례급성수계백혈병환자수궤분위2조,치료조30인,응용HAD방안유도치료,대조조28인수궤응용DA/HA방안유도치료。결과 HAD조유도화료완전완해솔(CR)위76.7%,부분완해솔(PR)위13.3%,총유효솔위90%,DA/HA방안유도화료완전완해솔(CR)위32.1%,부분완해솔(PR)위28.6%,총유효솔위60.7%,관찰조적완해솔급총유효솔명현고우대조조,P<0.05,차이유통계학의의,2조불량반응상당。HAD방안골수억제급립세포결핍엄중정도상대DA/HA중일사。결론 HAD방안유도화료치료급성수계백혈병료효우우DA/HA방안,차독부작용상당。
Objective Study clinical efficacy and adverse drug reaction of HAD regimen for acute myeloid leukemia. Methods 58 cases of acute myeloid leukemia patients were randomly divided into 2 groups, the treatment group of 30 patients were treated with HAD regimen, 28 cases in the control groups were treated with DA/HA group induction therapy. Results HAD group of induction chemotherapy complete remission (CR) rate was 76.7%, partial remission (PR) rate was 13.3%, the total effective rate was 90%. Complete remission induction chemotherapy of DA/HA regimen (CR) rate was 32.1%, partial remission (PR) rate was 28.6%, the total effective rate was 60.7%, relief and the rate of the observation group was better than that in control group, P<0.05. The difference was statistically signiifcant, adverse reaction in 2 groups were considerable. The HAD scheme of bone marrow suppression and agranulocytosis severity DA/HA were relatively heavier. Conclusion Take HAD regimen as induction chemotherapy in the treatment of acute myeloid leukemia curative effect is better than the DA/HA scheme, and has considerable side effects.